Neuropeptidni Y receptor

Pankreasni polipeptidni receptor 1
Identifikatori
Simbol	PPYR1
Alt. simboli	NPY4R, Y4, PP1
Entrez	5540
HUGO	9329
OMIM	601790
RefSeq	NM_005972
UniProt	P50391
Drugi podaci
Lokus	Hromozom 10 q11.2

Neuropeptidni Y receptor Y2
Identifikatori
Simbol	NPY2R
Entrez	4887
HUGO	7957
OMIM	162642
RefSeq	NM_000910
UniProt	P49146
Drugi podaci
Lokus	Hromozom 4 q31

Neuropeptidni Y receptor Y1
Identifikatori
Simbol	NPY1R
Alt. simboli	NPYR
Entrez	4886
HUGO	7956
OMIM	162641
RefSeq	NM_000909
UniProt	P25929
Drugi podaci
Lokus	Hromozom 4 q31.3-q32

Neuropeptidni Y receptor Y5
Identifikatori
Simbol	NPY5R
Entrez	4889
HUGO	7958
OMIM	602001
RefSeq	NM_006174
UniProt	Q15761
Drugi podaci
Lokus	Hromozom 4 q31-q32

Neuropeptidni Y receptori su klasa G-protein spregnutih receptora koje aktiviraju peptidni hormoni neuropeptid Y, peptid YY i pankreasni polipeptid.^[1] Ovi receptori učestvuju u kontroli raznovrsnog seta of procesa ponašanja, koji obuhvata apetit, cirkadijalni ritam, i anksioznost.^[2]^[3]^[4]^[5]^[6]^[7]

Aktivirani neuropeptidni receptori oslobađaju G_i podjedinicu iz heterotrimernog G proteinskog kompleksa. G_i podjedinica zatim inhibira produkciju sekundarnog glasnika cAMP iz ATP.

Tipovi

Poznata su četiri neuropeptid Y receptora kod sisara. Oni se označavaju sa: Y₁ do Y₅.^[8] Svaki od ovih receptora je kodiran zasebnim genom kod čoveka. Svi oni mogu da budu terapeutski ciljevi za gojaznost i druge poremećaje.^[9]^[10]^[11]

Y₁ - NPY1R
Y₂ - NPY2R
Y₄ - PPYR1
Y₅ - NPY5R

Literatura

↑ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). „XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors”. Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. ^{[mrtav link]}
↑ Heilig M (August 2004). „The NPY system in stress, anxiety and depression”. Neuropeptides 38 (4): 213–24. DOI:10.1016/j.npep.2004.05.002. PMID 15337373.
↑ Harro J (October 2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids 31 (3): 215–30. DOI:10.1007/s00726-006-0334-x. PMID 16738800.
↑ Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry 7 (17): 1645–59. DOI:10.2174/156802607782341037. PMID 17979774. ^{[mrtav link]}
↑ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery 1 (3): 315–24. DOI:10.2174/157488906778773689. PMID 18221213. ^{[mrtav link]}
↑ Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry 7 (17): 1710–20. DOI:10.2174/156802607782340966. PMID 17979780. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-08-09.
↑ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. DOI:10.1016/j.nut.2008.06.025. PMID 18725086.
↑ Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides 38 (4): 141–51. DOI:10.1016/j.npep.2004.06.002. PMID 15337367.
↑ Kamiji MM, Inui A (October 2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews 28 (6): 664–84. DOI:10.1210/er.2007-0003. PMID 17785427.
↑ MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry 7 (17): 1721–33. DOI:10.2174/156802607782341028. PMID 17979781. Arhivirano iz originala na datum 2013-01-12. Pristupljeno 2021-10-05.
↑ Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry 7 (17): 1734–42. DOI:10.2174/156802607782340957. PMID 17979782. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-10-05.

Spoljašnje veze

„Neuropeptide Y Receptors”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Arhivirano iz originala na datum 2016-03-03.
MeSH Neuropeptide+Y+Receptor

[pmid9549761-1] Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). „XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors”. Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. ^{[mrtav link]}

[pmid15337373-2] Heilig M (August 2004). „The NPY system in stress, anxiety and depression”. Neuropeptides 38 (4): 213–24. DOI:10.1016/j.npep.2004.05.002. PMID 15337373.

[pmid16738800-3] Harro J (October 2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids 31 (3): 215–30. DOI:10.1007/s00726-006-0334-x. PMID 16738800.

[pmid17979774-4] Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry 7 (17): 1645–59. DOI:10.2174/156802607782341037. PMID 17979774. ^{[mrtav link]}

[pmid18221213-5] Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery 1 (3): 315–24. DOI:10.2174/157488906778773689. PMID 18221213. ^{[mrtav link]}

[pmid17979780-6] Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry 7 (17): 1710–20. DOI:10.2174/156802607782340966. PMID 17979780. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-08-09.

[pmid18725086-7] Lindner D, Stichel J, Beck-Sickinger AG (September 2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. DOI:10.1016/j.nut.2008.06.025. PMID 18725086.

[pmid15337367-8] Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides 38 (4): 141–51. DOI:10.1016/j.npep.2004.06.002. PMID 15337367.

[pmid17785427-9] Kamiji MM, Inui A (October 2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews 28 (6): 664–84. DOI:10.1210/er.2007-0003. PMID 17785427.

[pmid17979781-10] MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry 7 (17): 1721–33. DOI:10.2174/156802607782341028. PMID 17979781. Arhivirano iz originala na datum 2013-01-12. Pristupljeno 2021-10-05.

[pmid17979782-11] Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry 7 (17): 1734–42. DOI:10.2174/156802607782340957. PMID 17979782. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-10-05.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]